number of access : ?
number of downloads : ?
ID 114819
Author
Kato, Yoshikane Kanaiso Hospital
Bando, Hiroshi Kanaiso Hospital|Tokushima University KAKEN Search Researchers
Matsuzaki, Sayuri Kanaiso Hospital
Waka, Shinnichi Kanaiso Hospital
Keywords
chronic kidney disease (CKD)
Metformin
Canagliflozin
erythropoiesis stimulating agent (ESA)
hypoxia-inducible factor (HIF)
Content Type
Journal Article
Description
The authors and colleagues have been involved in Non-Communicable Diseases (NCDs), especially including diabetes, chronic kidney disease (CKD) and hemodialysis. Some topics are described as possible therapy for CKD. (i) Metformin has inhibitory effect on cardiovascular events, and has an evidence for safe administration in mild to moderate renal impairment. (ii) Canagliflozin reduced moderately cardiovascular and renal outcomes across the primary and secondary prevention groups, from mega studies of CANVAS and CREDENCE. (iii) erythropoiesis stimulating agent (ESA) has been effective for improving anemia in HD for years. Some hypoxia-inducible factor (HIF) seems to be applied for clinical practice soon.
Journal Title
Pharmacy and Pharmacology International Journal
ISSN
23736367
Publisher
MedCrave Publishing
Volume
8
Issue
2
Start Page
87
End Page
89
Published Date
2020-04-15
Rights
©2020 Kato et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences